[Articles] Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis

4CMenB has an acceptable short-term safety profile. The primary course is sufficient to achieve a satisfactory immune response within 30 days of vaccination. A booster dose is required for children to prolong the protection against strain M10713, and the long-term immunogenicity against strain NZ98/254 remains suboptimal.

Source: The Lancet Infectious Diseases - January 19, 2018 Category: Infectious Diseases Authors: Maria Elena Flacco, Lamberto Manzoli, Annalisa Rosso, Carolina Marzuillo, Mario Bergamini, Armando Stefanati, Rosario Cultrera, Paolo Villari, Walter Ricciardi, John P A Ioannidis, Despina G Contopoulos-Ioannidis Tags: Articles Source Type: research